BrightSpring National Lecture Series - COVID-19 Response

1. COVID-19 RESPONSE - UPDATE AUGUST 12, 2020

2. AGENDA  Welcome  Company Overview  COVID-19 Update  Q&A  Summary and Next Steps John.Mudgett@rescare.com

3. COMPANY SNAPSHOT Company Uniquely Provides a Full Spectrum of Services to High Cost and “Must-Serve” Seniors and Specialty Clients / Patients with Significant Life-Long Chronic Health Needs Skilled Nursing, Senior Living, Hospital & Other LTC Pharmacy Services Home Health Care Neuro Therapies (Rehab) Behavioral (I/DD) Pharmacy Home Infusion Behavioral Health Specialty Drugs Workforce Rehabilitation Leading Provider of Diversified Home and Leading Provider of Diversified Home and Community Health and Pharmacy Services Community Health and Pharmacy Services to Medically Complex Patient Populations to Medically Complex Patient Populations 330,000+patients served daily across 50 states 9,000+clinical providers and pharmacists serving ~ 6,400+facilities

4. LEGACY VALUE SYSTEM DRIVES STRONG COMPANY CULTURE 11 DSPs won ANCOR’s “DSP of the Year” Award Over 300 “Working Smart, Doing Good” Caregiver Profiles New “Summit Award” and “Legacy of Care Award” Programs Over 20,000 peer-to-peer LEGACY recognitions made to date across the company – recognizing core behaviors in practice

5. DIFFERENTIATED PLATFORM AND CAPABILITIES Providing Pharmacy and Provider Services to the Highest Cost and Most Complex Populations

6. QUALITY 1STFRAMEWORK Enablers Driving Quality Technology Technology  Site Review App  Telecare; PERS  EHRs; QuickMAR (Rx)  ViewMasteRx  RxAllow and RxForecaster Culture and Auditing Culture and Auditing Training Training  “LEGACY” and "STARS"  Recognition programs  Accreditation  Ongoing/Targeted audits  Site review frequency, checklist, and data entry  Site Review Certification  Position Specific Training  Online Training; PMC Univ.  Ongoing Education Series  Ongoing Health Services Training Series  Pharmacist, Nurse Consulting Services Quality 1 Quality 1st stFramework Framework Data Analytics Data Analytics Signature Programs Signature Programs  Quality Review & Improvement Committee  Critical Incidents  Best-In-Class Scores  New Site Review Scores  Risk tiering sites with a QAPI focus  External survey and satisfaction results  You're Safe – I'm Safe  Fall, Pneumonia Prevention  Behavior Support  Food Preparation  Safe Home, Dementia Care  RxNow, RxSentry  TransitionRx, DischargeRx Committed to continuous quality and safety improvement demonstrated by significant investments Committed to continuous quality and safety improvement demonstrated by significant investments

7. QUALITY HIGHLIGHTS Strong Clinical and Quality Measures Across All Businesses that Exceed National Averages Neuro Therapies (Rehab) Neuro Therapies (Rehab) Behavioral Behavioral  Outstanding Value and Clinical Improvement Results: Outstanding Value and Clinical Improvement Results:  Industry Leading Investments in Quality and Monitoring Industry Leading Investments in Quality and Monitoring Drive Top Results in Care that Dramatically Reduces Cost: Drive Top Results in Care that Dramatically Reduces Cost:  40% - 70% reduction (53% combined average in Q3) in percent of patients requiring 24 hour supervision  4.3 satisfaction / likelihood to recommend (out of 5)   45% - 75% (58% combined avg in Q3) increase in percent of patients who can be left alone for 8 hours Behavioral Therapy Satisfaction Scores: 93% Very Satisfied / Satisfied (90% Very Satisfied); 72% NPS(1)   25% - 30% improvement in MPAI-4 (Mayo-Portland Adaptability Inventory) scores on key measures 35% zero deficiency surveys  > 50,000 home / site reviews per year  100% of H&C programs received CARF Accreditation  New Clinical oversight model rolled out in several states  Satisfaction Scores: 99.1% Very Satisfied / Satisfied  QuickMar (eMAR) and EHR implementations  Monitor behavioral incidents: <3% (# of events per qtr / census), supported by world class de-escalation training Workforce Services Workforce Services  Implementing new clinical coordination and oversight w/PREDICS: a proprietary predictive care planning model  Strong Key Performance Measures in Creating Jobs:  Four years of improving performance (84% in Q4)  Clients spend an average of 360 managed days at home 95% Customer Satisfaction  Strong data in Entered Employment, Retained Employment, Earnings, Attainment of Degree / Certificate, and Literacy and Numeracy Gains Hospitalization rate < 1%  Service Delivery (Performance Management) Team  Leading Manager training program (1) “NPS” is Net Promoter Score; NPS range is -100 to +100, therefore a “positive” score above 0 is considered “good,” +50 is “excellent,” and above 70 is considered “world class.”

8. BrightSpring-PharMerica has a Leading Pharmacy Platform that Connects Care Delivery Ecosystem Industry Leading Service Metrics Supported by a Unique Set of Value-Add Customer Products that are Differentiated  Extensive pharmacy offering and requirements across every client and patient served is a critical link between daily non- clinical services and periodic clinical services that drives improved outcomes and lower hospitalizations  Industry leading solutions to ensure accurate and timely access to medications, control pharmacy costs, and support customer education and remain in compliance with state and federal regulations Medication Availability Medication Availability Cost Containment Cost Containment Compliance & Education Compliance & Education  RxNow RxNow  PharMerica Formulary PharMerica Formulary  Pharmacist Consulting Pharmacist Consulting  EMR/EHR Interfaces EMR/EHR Interfaces  RxAllow RxAllow  EMR/EHR Interfaces EMR/EHR Interfaces  Electronic Prescribing Electronic Prescribing  RxForecaster; RxExact RxForecaster; RxExact  RxNow RxNow  Show ‘n Tell Show ‘n Tell  Quantity Limit Program Quantity Limit Program  EZ-MAR EZ-MAR  ViewMasteRx ViewMasteRx  Global Authorizations Global Authorizations  Medical Records Medical Records  TransitionRx TransitionRx  Split Billing Split Billing  Clinical Focus Areas Clinical Focus Areas  DischargeRx DischargeRx  Part D Plan Alerts Part D Plan Alerts  Nurse Consulting Services Nurse Consulting Services  RxSentry  ViewMasteRx ViewMasteRx  PMC University PMC University Ensure that Clients are Engaged Daily in the Patient Care Network through a Multitude of Unique Pharmacy Services Ensure that Clients are Engaged Daily in the Patient Care Network through a Multitude of Unique Pharmacy Services 89.59% Generic Dispensing Rate; 89.59% Generic Dispensing Rate; Savings Per Rx: $25 on Therapeutic Interchanges, Savings Per Rx: $25 on Therapeutic Interchanges, $ $22 from Split Billing, $21 from DischargeRx; $1.06 PPD Quantity Limit Program Savings; $0.10 Part D/MCD Non-Covered Charges 99.998% Order Accuracy; 99.998% Order Accuracy; 99.64% Order Completeness; 99.64% Order Completeness; 97.33% On-Time Delivery; 97.33% On-Time Delivery; Comprehensive and Real-Time Reporting Implementations Rated 4.8 (out of 5); Implementations Rated 4.8 (out of 5); Reduced F-Tags (below national average); Reduced F-Tags (below national average); Antibiotic Stewardship and Antipsychotic Antibiotic Stewardship and Antipsychotic Reduction clinical programs Reduction clinical programs

9. I/DD PHARMACY OVERVIEW  Pharmacy presence serving the in-home pharmacy needs of individuals with I/DD and other Behavioral Health / Mental Health conditions  Key I/DD Pharmacy Stats  Provides services to both affiliate and non-affiliate clients Patients with Three or More Chronic Conditions 57%  Services the majority of BrightSpring’s 24/7 Behavioral Health population Average Number of I/DD Patient Prescriptions  Non-affiliate represents greater than 60% of all persons served 9  PharMerica’s national institutional pharmacy platform creates meaningful growth opportunity by leveraging BrightSpring’s expertise serving the I/DD population 687K Total I/DD Patients (1)  Allows for expansion of I/DD pharmacy capabilities through existing PharMerica footprint  Significant benefits of scale and COGS-related synergies easily achievable in I/DD Pharmacy (2) 1. Represents I/DD patients in Supervised Residential Settings, which is BrightSpring’s expertise 2. Represents incremental $15MM EBITDA opportunity for I/DD pharmacy (represents potential I/DD patient capture by PharMerica pharmacies)

11. OVERVIEW OF COVID-19 RESPONSE  Company has been monitoring and managing the COVID-19 situation daily since February  New policies, protocols, training, and communications implemented across the enterprise, specific to COVID-19  Infection control measures, including limiting and stopping travel early on, shifting to remote work, and implementing guidelines for meetings  Dedicated team has worked to procure, distribute and train PPE and related supplies  Mandated visitor screenings and employee self-screenings and reporting daily  New tracking tools created  Management of employee and client/patient at-risk and sick situations, and sick leave and pay  IT support for tools, enabling remote work, etc.  Case identification and triage supported by nurse-led quality team  Quality team led Preparedness and Crisis Plans; Desktop Drills conducted  Partnered with states on key regulatory and funding considerations  Four peer-reviewed scientific papers published on our response thus far

12. OUTBREAK PREPAREDNESS AND ACTION COMMITTEE  The Committee’s mission is to prepare for potential outbreaks, and to act when necessary to protect, support and serve our patients, clients and employees, embodying the following guiding principles: − Preparation − − − − Reassurance Evidence-based Action Coordination Communication − Support  A comprehensive “BrightSpring-PharMerica Enterprise Outbreak Plan” was created and is regularly updated, August 1, 2020 version available here

13. OUTBREAK COMMITTEE CADENCE  Daily − − − Monitor Johns Hopkins COVID-19 Tracker and CDC and WHO Situation Rooms Monitor internally-developed COVID-19 tracking and screening app data Communications with Outbreak team and operational leadership  Weekly − − − Executive team live 5pm update and planning Company-wide email communications Communications with business segment leaders on preparedness and mitigation planning  Every Other Week − Full Outbreak Committee meeting − Update to Executive Committee

14. INTERNALLY DEVELOPED COVID-19 TRACKING & DATA VISUALIZATION APPLICATION  Each new case entered into the tracker auto triggers response from nursing / quality team who then reaches out to local operations to coordinate the response (triage, infection control, staffing, PPE plan)

15. INTERNALLY DEVELOPED EMPLOYEE SYMPTOM SCREENING APPLICATION  Any temperature of 100○F or higher or a positive symptom screen auto triggers notification of the employee’s supervisor

16. OVER ONE HUNDRED TWENTY COVID-19 EDUCATIONAL RESOURCES DEVELOPED  Live infection control sessions open to all employees have been conducted since February

17. NEW PATIENT/CLIENT DAILY CASES OF COVID-19 WITH 5 DAY MOVING AVERAGE Number of New Daily Patient or Client Cases With 5-day Moving Average 14 12 10 8 6 4 2 0

18. CUMULATIVE PATIENT & CLIENT CASES OF COVID-19 FIRST CASE THROUGH AUGUST 9, 2020 WITH 30-DAY FORWARD PROJECTION 1000 y = 99775ln(x) - 1E+06 R² = 0.9728 100 10 1 3/17/20 3/24/20 3/31/20 4/14/20 4/21/20 4/28/20 5/12/20 5/19/20 5/26/20 6/16/20 6/23/20 6/30/20 7/14/20 7/21/20 7/28/20 8/11/20 8/18/20 8/25/20 4/7/20 5/5/20 6/2/20 6/9/20 7/7/20 8/4/20 9/1/20 9/8/20

19. SUMMARY OF COVID-19 RESPONSE  Since the COVID-19 pandemic began in early 2020, BrightSpring-PharMerica has focused on implementing best practices in infection control, visitor management, employee screening, and streamlined reporting and triage protocols to optimally support clients, patients, employees, families and communities.  To date, we have experienced an overall infection rate of less than one percent less than one percent  We have reported our preparation plan, tactics, experience and data in numerous peer- reviewed research publications (next slide), and the World Health Organization, the International Long Term Care Network, and the London School for Economics have included our publication(s) in their policy briefs

20. LEADING THE WAY IN OUTBREAK SUPPRESSION: PUBLISHING OUR OUTCOMES IN FOUR DIFFERENT SPACES IN LEADING PEER-REVIEWED JOURNALS Home Health Care/Personal Home Care Intellectual/Developmental Disability * Top 5% of all Research Articles Ever Tracked by Altmetric * * Top 5% of all Research Articles Ever Tracked by Altmetric * * #2 Most Read Article in the Journal in the last 6 mo * * #2 Most Read Article in the Journal in the last 6 mo * Pharmacy and Long Term Care Primary Care and Assisted Living

21. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH  In the 100-day period between 20 January 2020 and 30 April 2020, we provided continuous support for 11,540 individuals with IDD.  64% of the individuals were in residential, community settings, and 36% were in intermediate care facilities.  The average age of the cohort was 46 ± 12 years, and 60% were male.  122 individuals with IDD were placed in quarantine for exhibiting symptoms and signs of acute infection such as fever or cough.  66 individuals tested positive for SARS-CoV-2, and their average age was 50.  The positive individuals were located in 30 different homes (1.3% of total) across 14 states.  15 homes had single cases, and 15 had more than one case.

22. HOW COVID-19 POSITIVE PEOPLE WITH IDD FARED IN THE FIRST 100 DAYS Strong infection control and outbreak mitigation tactics have led to low infection, hospitalization and fatality rates

23. GOOD PRESS

24. VOLUNTARY COVID-19 VACCINE TRIAL OPPORTUNITY  Headlands Research, a clinical trial site company that conducts clinical trials at its sites throughout North America, has been selected for multiple COVID-19 vaccine and treatment trials, and is offering the opportunity to BrightSpring-PharMerica employees.  If you qualify to participate, there’s no cost to you. Compensation will be offered to trial enrollees.  These vaccines do NOT contain the live virus. Instead, they activate the immune system to produce antibodies against certain components of the SARS-coV-2 virus.  Participants must complete follow up (symptom questionnaires, blood tests, etc.), but other than that they should plan to go about their regular business living their lives. There is NO specific viral challenge in these studies. People may be exposed or not exposed based in the communities in which they live and through their regular daily activities. As such, there wouldn’t be any specific or additional risk to our clients/patients/employees from employee participation.

25. POSITIVE LONG TERM BUSINESS IMPACTS FROM OUTBREAK RESPONSE Outbreak Impacts Expected to Have Longer Term Benefits to BrightSpring-PharMerica Outbreak Impacts Expected to Have Longer Term Benefits to BrightSpring-PharMerica  Interdisciplinary team quickly developed strategy and executed on tactics to suppress virus transmission  Intranet education and My Policies built out (over 120 resources)  Enhanced Enterprise wide-infection control policy, live, cross country education roll out  Consolidated Crisis Communications  Tracking of Enterprise-wide average daily census of cases  Development of a Central Supply function and mass procurement and distribution of scarce PPE supplies  Agile, rapid development and launch of three new technologies within four weeks (COVID-19 tracking, Employee Screening app, Enterprise “War Room” Business Intelligence dashboard)  Enterprise location map  Development of Point of Care Diagnostic Testing Capabilities  Telehealth offerings expedited  Use of Novel Predictive Modeling (community-based thermometers to predict outbreak clusters, hospital utilization models, etc)

27. AGENDA  Welcome  Company Overview  COVID-19 Update  Q&A  Summary and Next Steps John.Mudgett@rescare.com